Finance

Lists
Why is NCYT down 2.65%?
Dive Deeper
NCYT:LON
Novacyt SA
GBX 40.40
-2.65%
(-1.10) 1D
Oct 9, 4:35:02 PM GMT+1  ·   GBX
All symbols
SymbolPriceChange% Change
Generating top insights for NCYT...
Open
GBX 39.10
High
GBX 41.56
Low
GBX 39.10
Mkt. cap
32.68M
Avg. vol.
96.38K
Volume
147.26K
52-wk high
GBX 86.00
52-wk low
GBX 26.60
Shares outstanding
37.66M
No. of employees
228
Open
GBX 39.10
High
GBX 41.56
Low
GBX 39.10
Mkt. cap
32.68M
Avg. vol.
96.38K
Volume
147.26K
52-wk high
GBX 86.00
52-wk low
GBX 26.60
Shares outstanding
37.66M
No. of employees
228
News stories
From web sources and news partners
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA
CEODavid Allmond
Employees228
FoundedJul 3, 2006
Headquarters-
SectorBiotechnology
Previous reportsAll values in GBP
Loading Previous Earnings...
Revenue
Net income
All values in GBP
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
5.12M
5.12M
5.78M
5.78M
Cost of goods sold
2.61M
2.61M
2.56M
2.56M
Cost of revenue
2.61M
2.61M
2.56M
2.56M
Research and development expenses
1.03M
1.03M
1.06M
1.06M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.69M
4.69M
4.65M
4.65M
Operating expense
5.54M
5.54M
5.66M
5.66M
Total operating expenses
8.16M
8.16M
8.22M
8.22M
Operating income
-3.04M
-3.04M
-2.44M
-2.44M
Other non operating income
-23.00K
-23.00K
-47.50K
-47.50K
EBT including unusual items
-10.16M
-10.16M
-2.91M
-2.91M
EBT excluding unusual items
-2.52M
-2.52M
-2.80M
-2.80M
Income tax expense
-1.81M
-1.81M
-49.50K
-49.50K
Effective tax rate
17.85%
17.85%
1.70%
1.70%
Other operating expenses
-180.50K
-180.50K
-44.00K
-44.00K
Net income
-8.27M
-8.27M
-2.90M
-2.90M
Net profit margin
-161.60%
-161.60%
-50.13%
-50.13%
Earnings per share
-
-
-
-
Interest and investment income
149.00K
149.00K
63.00K
63.00K
Interest expense
-146.00K
-146.00K
-139.00K
-139.00K
Net interest expenses
3.00K
3.00K
-76.00K
-76.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
3.46M
3.46M
-1.88M
-1.88M
Gain or loss from assets sale
-3.00K
-3.00K
8.00K
8.00K
AI content may include mistakes. Learn more
Google apps